Business address is a home office apartment, I guess.
1.Breakthrough Diagnostic, Inc.: 45 Wall Street, Suite 920, New York NY 10005
a.80.01% owned by Amarantus
b.Gerald Commissiong, CEO and sole director
2.Elto Pharma, Inc.: 45 Wall Street, Suite 920, New York, NY 10005
a.50%-owned by Amarantus
b.Gerald Commissiong, CEO and sole director
3.Cutanogen Corporation: 45 Wall Street, Suite 920, New York, NY10005
a.Gerald Commissiong, CEO and sole director
b.100% owned by Amarantus
4.MANF Therapeutics, Inc.: 45 Wall Street, Suite 920, New York,NY10005
a.Gerald Commissiong, CEO and sole director
b.100% owned by Amarantus.
5.AMBS Operations LLC: 45 Wall Street, Suite 920, New York, NY 10005
a.Gerald Commissiong, Manager
b.100% owned by Amarantus
Wholly-owned subsidiaries
(i)Hemp BioHealth, Inc.that is seeking to develop inhalable non-psychoactive cannabinoid products for the smoking cessation and other CNS-related disorders;
(ii)Cutanogen Corporationthat is preparing to initiate a potentially pivotal clinical development program for the autologous, full thickness skin grafting program Engineered Skin Substitute (“ESS”) for the treatment of large, life-threateningpediatric severe burns, with significant additional potential applications in the treatment of critical care and cosmetic-related applications;
(iii)MANF Therapeutics, Inc.that is developing the pre-clinical stage protein drug candidate mesencephalic astrocyte-derived neurotrophic factor ("MANF"
for the treatment of vision loss associated with the rare genetic condition Wolfram’s Syndrome, as well as the treatment of other vision-related disorders such as retinitis pigmentosa, glaucoma and macular degeneration. Additionally, MANF has potential applications in the treatment of Parkinson’s disease, diabetes and several other conditions;
(iv)Trimeric Labs, Inc. thatis further exploiting the neurotrophic factor discovery platform “PhenoGuard” from which MANF was discovered. Trimeric is seeking to discover additional neurotrophic factors from PhenoGuard as potential treatments for Parkinson’s disease, Alzheimer’s disease, Huntington’s disease, ALS, and other neurological conditions;
Partially-owned subsidiaries
(i)XX.X% ownership in Todos Medical Ltd. (based in Israel, NASDAQ: TOMD)that is developing the TBIA cancer blood testing platform focused on the early detection of breast cancer, colon cancer and lung cancer as well as the Alzheimer’s blood diagnostic LymPro Test® as a pre-symptomatic blood test for Alzheimer’s disease, as well as potentially for the early diagnosis of CTE;
(ii)50% ownership in Elto Pharma, Inc. that is preparing to initiate a Phase 2b clinical trial for the small molecule drug candidate eltoprazine forthe treatment of Parkinson’s disease levodopa-induced dyskinesia (PD-LID), with additional potential applications for the treatment of agitation in Alzheimer’s disease and adult attention deficit and hyperactivity disorder (adult ADHD);
(iii)32.4% common stock ownership in Avant Diagnostics, Inc. (OTCPK: AVDX) that is commercializing the phosphoprotein tumor analysis platform Theralink® to improve diagnosis and treatment response rates across all cancers.
1.Breakthrough Diagnostic, Inc.: 45 Wall Street, Suite 920, New York NY 10005
a.80.01% owned by Amarantus
b.Gerald Commissiong, CEO and sole director
2.Elto Pharma, Inc.: 45 Wall Street, Suite 920, New York, NY 10005
a.50%-owned by Amarantus
b.Gerald Commissiong, CEO and sole director
3.Cutanogen Corporation: 45 Wall Street, Suite 920, New York, NY10005
a.Gerald Commissiong, CEO and sole director
b.100% owned by Amarantus
4.MANF Therapeutics, Inc.: 45 Wall Street, Suite 920, New York,NY10005
a.Gerald Commissiong, CEO and sole director
b.100% owned by Amarantus.
5.AMBS Operations LLC: 45 Wall Street, Suite 920, New York, NY 10005
a.Gerald Commissiong, Manager
b.100% owned by Amarantus
Wholly-owned subsidiaries
(i)Hemp BioHealth, Inc.that is seeking to develop inhalable non-psychoactive cannabinoid products for the smoking cessation and other CNS-related disorders;
(ii)Cutanogen Corporationthat is preparing to initiate a potentially pivotal clinical development program for the autologous, full thickness skin grafting program Engineered Skin Substitute (“ESS”) for the treatment of large, life-threateningpediatric severe burns, with significant additional potential applications in the treatment of critical care and cosmetic-related applications;
(iii)MANF Therapeutics, Inc.that is developing the pre-clinical stage protein drug candidate mesencephalic astrocyte-derived neurotrophic factor ("MANF"
for the treatment of vision loss associated with the rare genetic condition Wolfram’s Syndrome, as well as the treatment of other vision-related disorders such as retinitis pigmentosa, glaucoma and macular degeneration. Additionally, MANF has potential applications in the treatment of Parkinson’s disease, diabetes and several other conditions; (iv)Trimeric Labs, Inc. thatis further exploiting the neurotrophic factor discovery platform “PhenoGuard” from which MANF was discovered. Trimeric is seeking to discover additional neurotrophic factors from PhenoGuard as potential treatments for Parkinson’s disease, Alzheimer’s disease, Huntington’s disease, ALS, and other neurological conditions;
Partially-owned subsidiaries
(i)XX.X% ownership in Todos Medical Ltd. (based in Israel, NASDAQ: TOMD)that is developing the TBIA cancer blood testing platform focused on the early detection of breast cancer, colon cancer and lung cancer as well as the Alzheimer’s blood diagnostic LymPro Test® as a pre-symptomatic blood test for Alzheimer’s disease, as well as potentially for the early diagnosis of CTE;
(ii)50% ownership in Elto Pharma, Inc. that is preparing to initiate a Phase 2b clinical trial for the small molecule drug candidate eltoprazine forthe treatment of Parkinson’s disease levodopa-induced dyskinesia (PD-LID), with additional potential applications for the treatment of agitation in Alzheimer’s disease and adult attention deficit and hyperactivity disorder (adult ADHD);
(iii)32.4% common stock ownership in Avant Diagnostics, Inc. (OTCPK: AVDX) that is commercializing the phosphoprotein tumor analysis platform Theralink® to improve diagnosis and treatment response rates across all cancers.
